Skip to Content

What is the success rate of Cabometyx (cabozantinib)?

Medically reviewed by N. France, BPharm. Last updated on Feb 26, 2021.

Official Answer

by Drugs.com

Cabometyx (cabozantinib) is a tyrosine kinase inhibitor used to treat patients with advanced renal cell carcinoma or hepatocellular (liver) cancer.

It is a chemotherapy drug that you take until your cancer starts to get worse - disease progression - or you can no longer tolerate the drug because of side effects or adverse reactions.

How successful Cabometyx is can be measured by how long patients take the treatment for, how long they survive for without their cancer getting worse (progression-free survival), how many months they remain alive for while taking the treatment and how many patients respond to the drug.

How effective is Cabometyx?

Trial Duration of treatment Median progression-free survival (PFS), overall survival (OS) and overall response rate (ORR)
METEOR - advanced renal cell carcinoma Cabometyx: 7.6 months (range 0.3 - 20.5)
vs
Everolimus (Afinitor): 4.4 months (range 0.21 - 18.9)
PFS
Cabometyx: 7.4 months (95% CI 5.6, 9.1)
vs
Everolimus: 3.8 months (95% CI 3.7, 5.4)

OS
Cabometyx: 21.4 months (95% CI 18.7, NE)
vs
Everolimus: 16.5 months (95% CI 14.7, 18.8)

ORR
Partial responses only
Cabometyx: 17% (95% CI 13%, 22%)
vs
Everolimus: 3% (95% CI 2%, 6%)
CABOSUN - advance renal cell carcinoma Cabometyx: 6.5 months (range 0.2 - 28.7)
vs
Sunitinib (Sutent): 3.1 months (range 0.2 - 25.5)
PFS
Cabometyx: 8.6 months (95% CI 6.8, 14.0)
vs
Everolimus: 5.3 months (95% CI 3.0, 8.2)

ORR
Partial responses only
Cabometyx: 20% (95% CI 12%, 30.8%)
vs
Everolimus: 9% (95% CI 3.7%, 17.6%)

CHECKMATE-9ER - advanced renal cell carcinoma, first-line treatment Cabometyx plus nivolumab (Opdivo): 14 months (range 0.2 - 27) PFS
Cabometyx: 16.6 months (95% CI 12.5, 24.9)
vs
Sunitinib: 8.3 months (95% CI 7.0, 9.7)

OS
Cabometyx: Not reached
vs
Sunitinib: Not reached

ORR
Complete and partial responses
Cabometyx: 55.7% (95% CI 50.1, 61.2)
vs
Sunitinib: 27.1% (95% CI 22.4, 32.3)
CELESTIAL - advanced hepatocellular carcinoma Cabometyx: 3.8 months (range 0.1 - 37.3)
vs
Placeo: 2.0 months (range 0.0 - 27.2)
PFS
Cabometyx: 5.2 months (95% CI 4.0, 5.5)
vs
Placebo: 1.9 months (95% CI 1.9, 1.9)

OS
Cabometyx: 10.2 months (9.1, 12.0)
vs
Placebo: 8.0 months (6.8, 9.4)

ORR
Partial responses only
Cabometyx: 4% (95% CI2.3, 6.0)
vs
Placebo: 0.4% (95% CI 0.0, 2.3)

References

Related Medical Questions

Drug Information

Related Support Groups